ArticleExperimental brain research2026
Liraglutide reduces the apoptosis of feeding and appetite-suppressing neurons in the hypothalamus of obese rats association with the PI3K/AKT/Foxo1 pathway.
Article in Experimental brain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveObesity-induced inflammation in the hypothalamus disrupts the function of neurons that regulate appetite, particularly proopiomelanocortin (POMC) and neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons in the arcuate nucleus (ARC). Although Liraglutide, a GLP-1 analogue, exhibits neuroprotective properties, the underlying molecular mechanisms are unclear. In this study, we investigated whether Liraglutide protects hypothalamic neurons via the PI3K/AKT/Foxo1 pathway.
methodsMale SD rats (n = 40) were fed a high-fat (HFD) or normal-fat (NFD) diet for 12 weeks. The obese rats on the HFD received Liraglutide (200 µg/kg/day, HL) or saline (HS), while the NFD controls received Liraglutide (NL) or saline (NS) for 6 weeks. Metabolic parameters, neuronal ultrastructure (TEM/Nissl staining), apoptosis (TUNEL assay) and biomarkers of the PI3K/AKT/Foxo1 pathway were analysed using immunofluorescence, RT-PCR and Western blotting.
resultsThe HFD group showed more weight gain, higher fasting blood glucose levels, and insulin resistance compared to the NFD. Rats on the HFD showed neuronal damage (reduced Nissl bodies and nuclear fragmentation) and apoptosis (more TUNEL-positive cells) in the ARC. Liraglutide reversed these effects. The HL group showed lower levels of apoptosis compared to the HS group. At the same time, there was an increase in the activity of the POMC and a decrease in the NPY/AgRP (p < 0.05). Mechanistically, Liraglutide activates the PI3K/AKT pathway, reduces Foxo1 expression and balances Bcl-2/Bax apoptotic regulators.
conclusionLiraglutide improves hypothalamic neuronal apoptosis in obesity by activating the PI3K/AKT signalling pathway, which reduces Foxo1-mediated apoptosis and brings the balance of POMC and NPY neurons back to normal. These findings explain a key mechanism of Liraglutide's anti-obesity effects and demonstrate its potential for neuroprotection.
Indexed as
Identifiers
41865318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.